South Korea-based Samsung Biologics has announced a new agreement with Bristol Myers Squibb (BMS) for large-scale manufacturing of BMS' commercial antibody cancer drug substance.

BMS and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company's latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea. 

To maximize operational efficiency and expand capabilities in response to growing biomanufacturing demands, Samsung Biologics fully completed Plant 4, which will further advance the company's standing as the world's largest manufacturing facility at a single site, holding a 604KL total capacity, and announced plans to construct Plant 5, which will be operational in April 2025. 

"Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world," said John Rim, President and CEO of Samsung Biologics. "This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity."